Holen Sie sich die Stockscreener-App
3.3861
1.78%
-0.0161
Schlusskurs vom Vortag:
$3.37
Offen:
$3.33
24-Stunden-Volumen:
17,997
Relative Volume:
0.10
Marktkapitalisierung:
$39.51M
Einnahmen:
$12,000
Nettoeinkommen (Verlust:
$-48.41M
KGV:
-0.1971
EPS:
-17.181
Netto-Cashflow:
$-19.99M
1W Leistung:
+1.22%
1M Leistung:
+4.91%
6M Leistung:
-21.75%
1J Leistung:
-79.77%
1-Tages-Spanne:
$3.30
$3.3975
1-Wochen-Bereich:
$3.1295
$3.4427
52-Wochen-Spanne:
$2.49
$20.31
Incannex Healthcare Inc Stock (IXHL) Company Profile
Firmenname
Incannex Healthcare Inc
Sektor
Telefon
61 409 840 786
Adresse
8 CENTURY CIRCUIT, NORWEST NSW
Compare IXHL vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IXHL
Incannex Healthcare Inc
|
3.3019 | 40.32M | 12,000 | -48.41M | -19.99M | -17.18 |
TAK
Takeda Pharmaceutical Co Adr
|
18.30 | 58.50B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.81 | 42.84B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.155 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.48 | 30.40B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
496.69 | 21.36B | 3.17B | 1.29B | 1.01B | 27.09 |
Incannex Healthcare Inc Aktie (IXHL) Neueste Nachrichten
Incannex begins Phase 2 dosing study for sleep apnea drug - Investing.com
A company with about $70 million in cash and no debt is testing a sleep-apnea treatment. - Stock Titan
Why Did IXHL Stock Tank Over 32% Today? - Stocktwits
Enterprise value to EBIT forward of Incannex Healthcare Limited – LSX:A2DF4D - TradingView
IXHL Q4'26 Earnings: EPS estimate is (0.14) USD - TradingView
Incannex Healthcare (IXHL) Slides 4.97% to $3.46, Testing Support at $3.29ETF Premium Discount - vinanet.vn
What’s Next for Incannex Healthcare (ASX:IHL) After US Patent Win? - kalkinemedia.com
Incannex doses first patient in sleep apnea drug trial By Investing.com - Investing.com Nigeria
Incannex doses first patient in sleep apnea drug trial - Investing.com India
Incannex (IXHL) Advances Sleep Apnea Drug Trial Amid High Price-to-Sales Valuation - GuruFocus
Incannex Healthcare Doses First Patient in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea - Quiver Quantitative
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X - Barchart.com
Sleep-apnea candidate showed up to 83% fewer breathing interruptions; Incannex doses first patient - Stock Titan
IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms - Stocktwits
Incannex Healthcare (ASX:IHL) Cash Flow Check: What Investors Need to Watch on 19 August - kalkinemedia.com
Why Is Incannex Healthcare (ASX:IHL) in Market Focus? - Kalkine Media
Incannex Wins US Patent Lift For Sleep Apnoea Pipeline (ASX:IHL) - Kalkine Media
Incannex Healthcare (IXHL) Shows Modest Uptick, Holding Key Support Amid Clinical Pipeline FocusTrend Continuation Trade - vinanet.vn
Incannex Healthcare (IXHL) Climbs 3.8% to $3.28, Testing Key Resistance ZoneMcClellan Summation - vinanet.vn
Polar Asset Management (IXHL) reports 7.0% beneficial stake via 900,000 warrants - Stock Titan
$Incannex Healthcare (IXHL.US)$ - Moomoo
Incannex (ASX:IHL): What Is Changing in the Liquidity Test? - Kalkine Media
Why Does Incannex Healthcare (ASX:IHL) Shape Discipline? - Kalkine Media
Incannex Healthcare (ASX:IHL) Clinical Development Pipeline: Market Outlook - Kalkine Media
Incannex Healthcare Inc. (IXHL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incannex Healthcare Inc. (IXHL) options chain - Yahoo Finance Singapore
Incannex Secures A$5.1M R&D Tax Incentive Refund - The Globe and Mail
Why Are Incannex Healthcare (ASX:IHL), Cann Group (ASX:CAN), ECS Botanics (ASX:ECS) and Little Green Pharma (ASX:LGP) Back in the Market Spotlight? - Kalkine Media
Why Are BrainChip (ASX:BRN), Incannex Healthcare (ASX:IHL), Lake Resources (ASX:LKE) and Cann Group (ASX:CAN) Back in the Market Spotlight? - kalkinemedia.com
Incannex receives final A$5.1m R&D tax incentive refund By Investing.com - Investing.com UK
Incannex Healthcare Inc. (IXHL) stock price, news, quote and history - Yahoo Finance Singapore
Incannex receives final A$5.1m R&D tax incentive refund - Investing.com
Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 - The Manila Times
Form 8K Incannex Healthcare Inc. For: 11 August By Investing.com - Investing.com Nigeria
Press Release: Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 - Moomoo
Incannex receives A$5.1M final R&D refund, totaling A$11.2M non-dilutive funding - TradingView
Can Incannex (ASX:IHL) Reshape The Cannabis Conversation? - kalkinemedia.com
Incannex Healthcare Inc (IXHL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Incannex Healthcare Inc. (IXHL) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Incannex Healthcare Inc (IXHL) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Incannex Healthcare Inc. Revenue Breakdown – NASDAQ:IXHL - TradingView
IXHL|Incannex Healthcare Inc|Price:2.985|Chg%:+0.035 - TradingKey
Incannex Healthcare Inc (IXHL) Institutional Confidence - TradingKey
Incannex Healthcare Inc (IXHL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Incannex Healthcare Inc (IXHL) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
Incannex Healthcare Inc (IXHL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Incannex Healthcare Inc. Commences Participant Screening In Dreamzz Phase 2 Study Of IHL-42X For Obstructive Sleep Apnea - marketscreener.com
Incannex starts screening for Phase 2 study of IHL-42X to treat obstructive sleep apnea with FDA Fast Track status - Pluang
Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea - The Manila Times
Incannex Commences Screening in Phase 2 DReAMzz Study of IHL-42X for OSA - TradingView
Finanzdaten der Incannex Healthcare Inc-Aktie (IXHL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):